highest incidence of esophageal cancer is in Asia and eastern and southern Africa. In some areas of China, reported incidence rates are 10-to 100-fold more than the incidence in the United States. 3 The principle histologic types of esophageal cancer are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). The relative frequency of histologic subtypes differs greatly by geographical location. Over the last 30 years in Western Europe, North America, and Australia, there has been a dramatic shift in the histological subtypes from squamous cell to adenocarcinoma. 4, 5 This has been attributed to a decline in smoking and an increase in adenocarcinoma risk factors including obesity, gastro-esophageal reflux disease, and Barrett's esophagus. Adenocarcinoma has increased by an alarming 450% among white men in the last three decades. 5 In Asia, where environmental toxins other than tobacco and alcohol may play a role in the origin of esophageal cancer, ESCC continues to be most common and constitutes a major health problem, particularly in China. 6 Approximately 50% of esophageal cancers are localized or locoregionally advanced at diagnosis, and thus, amenable to potentially curative locoregional therapy. 5 Five-year survival rates for all patients with esophageal cancer have shown modest improvements over the past 35 years from 5% to approximately 20% for patients diagnosed in 1975 and 2004, respectively. 5 Survival for locoregionally advanced disease treated with surgery alone has been consistently poor, ranging from 6% to 26% in published series. [7] [8] [9] The high incidence of recurrence, both local and distant, after ostensibly curative surgery has provided the impetus for many studies of multimodality therapy incorporating radiation and/or chemotherapy, primarily in the neoadjuvant setting, aimed at reducing the overall risk of relapse and death. Unfortunately, the appropriate management of locally advanced disease has been contentious for a number of years, and no clear standard of care has been defined that could be accepted worldwide. For patients with adenocarcinoma, there are clinical trial data supporting the various approaches of induction concurrent chemo-radiation (CRT), induction chemotherapy, perioperative chemotherapy, or resection after adjuvant CRT. Recent data suggest that preoperative CRT is superior to surgery alone. 10 This review will focus on recent therapeutic developments for esophageal cancer, including the recently published phase III clinical trials for both resectable and metastatic disease and ongoing trials evaluating targeted therapy and biomarkerdriven investigations. Given the particularly high burden of esophageal cancer in Asia, randomized studies of esophageal cancer therapy conducted in Asian populations will be with squamous cancer, suggested a survival advantage for preoperative therapy of 12% at 5 years. 15 Notably, this study did not have a surgery-only control arm.
Several phase III studies of perioperative chemotherapy, primarily looking at gastric cancer, have enrolled subpopulations of patients with lower esophageal or gastro-esophageal junction (GEJ) adenocarcinoma. The MAGIC study conducted in the United Kingdom included 26% of patients with lower esophageal or GEJ adenocarcinoma. 16 This study demonstrated a 13% improvement in 5-year survival for patients who received multiagent epirubicin, cisplatin, and fluorouracil (ECF) chemotherapy for three cycles preoperatively followed by another three cycles, postoperatively. Subgroup analyses suggested that the trend for improved survival was preserved in the group of patients with lower esophageal or GEJ tumors. A French study by Ychou et al. 13 randomized 224 adenocarcinoma patients (72% esophageal or GEJ tumors) to two or three cycles of preoperative cisplatin/5-flourouracil (FU) followed by three or four cycles of postoperative therapy; of note, only 50% of patients who received at least one cycle of preoperative chemotherapy actually received postoperative therapy. Despite closing early because of poor recruitment, this study showed at 5 years a significant survival advantage of 14% in favor of the chemotherapy group over surgery alone. In 2011, a meta-analysis of preoperative chemotherapy suggested a hazard ratio (HR) for all-cause mortality of 0.87 (95% confidence interval [CI], 0.79-0.96) in favor of chemotherapy, compared with surgery alone, which translated to a 2-year absolute survival advantage of 5%. 17 Analysis by histology suggested a significant benefit to neoadjuvant chemotherapy for adenocarcinoma, HR 0.83 (0.71-0.95; p = 0.01), however, the benefit for squamous tumors did not reach significance, HR 0.92 (0.81-1.04; p = 0.18). At present, we consider perioperative However, this study encouraged the adoption of multimodality therapy as a standard of care in the United States. Subsequently, several other studies published during the 2000s failed to support a survival advantage for the multimodality approach. [18] [19] [20] Many of these studies had flaws, including utilizing suboptimal chemotherapy and radiation schedules, 19 being statistically underpowered, 20 or adopting lower radiation dosing. 21 Importantly, these studies did suggest that achieving pCR was prognostically important after preoperative therapy with a significant improvement in overall survival (OS) for those achieving pCR. 19 The U.S. CALGB 9781 study, which closed early because of poor recruitment, did report a significant survival advantage for multimodality therapy. However, because of the small number of patients enrolled, (56 in total, 75% adenocarcinoma), the wider relevance of the results were questionable. 21 In France, Mariette et al. 22 reported a 13-month increase in OS for multimodality over surgery alone, but this difference did not meet statistical significance. Most recently, the Dutch CROSS study, published in 2012, confirmed the benefits of multimodality treatment in esophageal cancer. 10 This large, well-conducted study examined weekly, lowdose, radio-sensitizing carboplatin (area under the curve 2)/ paclitaxel (50 mg/m 2 ) chemotherapy for 5 weeks concurrent with a standard radiation schedule followed by surgery compared with surgery alone. Patients predominantly had adenocarcinoma (74.7%), with 24% having tumors of the GEJ. Multimodality treatment was well tolerated with more than 90% of patients receiving all the scheduled chemotherapy and radiation. R0 resections were significantly more frequent after preoperative therapy (92% versus 69% for surgery alone, p < 0.001), lymph-node positivity at resection was markedly reduced by preoperative therapy (31% versus 75%, p < 0.001 for surgery alone), and there was no increase in postoperative morbidity or mortality. Median OS was more than doubled for patients who received multimodality therapy (49.4 months versus 24 months for surgery alone, p = 0.011), and the benefit of multimodality therapy seemed to be preserved across tumor histological subtypes and all other stratified variables. Interestingly, in this study although there was a higher rate of pCR with preoperative therapy for squamous (49%) compared with adenocarcinomas (23%), this did not translate into better outcomes for patients with squamous histology.
Sequential chemo-radiation, postoperative chemotherapy, and other strategies
In contrast to concurrent preoperative chemo-radiation, several studies have demonstrated no benefit to sequentially administered preoperative chemotherapy followed by radiation when compared with surgery alone, and as a consequence, we do not recommend this strategy. 23, 24 Several studies have addressed the role of induction chemotherapy followed by CRT before surgery. The German POET study compared 15 weeks of preoperative chemotherapy alone (cisplatin/5FU) with sequential treatment of 12 weeks of induction chemotherapy, followed by preoperative chemo-radiation (cisplatin/etoposide) in 126 patients with gastric cardia or GEJ tumors. 25 This study was closed early because of poor accrual, however, there was a strong trend toward improved 3-year survival for patients who received preoperative CRT (3-year survival: chemo 27.7%, CRT 47.4%, p = 0.07). In addition, patients who received CRT had significantly higher pCR rates (15.6% versus 2.0% for chemo alone, p = 0.03) and negative lymph node status at surgery (64.4% versus 37.7% for chemo alone, p = 0.01). In Sweden, a randomized study of 91 patients, comparing one cycle of induction chemotherapy before CRT versus surgery alone, failed to demonstrate a benefit for induction chemotherapy followed by CRT. 26 More recently, a phase II study evaluated induction chemotherapy with cisplatin/irinotecan followed by the same chemotherapy concurrent with radiation in 55 patients with operable esophageal cancer. 27 The pCR rate in this study was relatively low at 16% with modest progression-free survival (PFS) and OS rates.
Although data from the POET study are promising, because of the lack of a preoperative CRT-alone arm in that study, questions remain regarding the true role of induction chemotherapy before CRT in multimodality treatment of esophageal cancer. Given the results of the larger CROSS study, which did not incorporate induction chemotherapy and showed excellence tolerability of CRT, at present we favor CRT without induction chemotherapy for the majority of our patients.
For good performance status patients with resected node-positive GEJ tumors, who have not received preoperative therapy, adjuvant CRT should be considered. The U.S. Intergroup study randomly assigned 556 patients with resected gastric (80%) or GEJ (20%) adenocarcinoma to observation or adjuvant chemo-radiation with 5-FU/leucovorin (4 cycles, 2 during radiation). 28 Median OS was significantly increased for patients who received adjuvant chemo-radiation (surgery alone 27 months versus adjuvant CRT 36 months, p = 0.005). Recently updated analyses of this study confirm a persistent survival benefit at 10 years from adjuvant CRT. 29 The optimal treatment for patients with resected esophageal squamous carcinoma is unclear, with some single-arm studies and retrospective data indicating a benefit from adjuvant CRT and some others suggesting that the contribution of radiation may be marginal. 30, 31 The benefit of adjuvant chemotherapy for resected esophageal squamous carcinoma was assessed in a Japanese study, which compared surgery alone with surgery followed by adjuvant cisplatin/5-FU in 242 patients. 32 This study met its primary endpoint of improving disease-free survival (45% of 5-year disease-free survival for surgery alone versus 55% for adjuvant chemotherapy; p = 0.037), however, OS was not significantly improved (52% versus 61%).
Nonsurgical Management of Esophageal Cancer

Definitive CRT
The landmark trial of definitive CRT was the RTOG 85-01 study, in which patients with locally advanced esophageal cancer were randomized to chemo-radiotherapy or radiotherapy alone. 33, 34 Chemotherapy consisted of 5-FU (1000 mg/ m 2 /24 hours × 4 days) and cisplatin (75 mg/m 2 , day 1), which was given on the first day of weeks 1, 5, 8, and 11. Radiation therapy (5000 cGy/25 fractions) was begun concurrently with day 1 of chemotherapy. Four cycles of chemotherapy were given-two during radiotherapy and two after radiotherapy. The control arm consisted of radiation alone of 6400 cGy in 32 fractions. Only 50% of patients were able to complete all four cycles of chemotherapy. Patients receiving CRT had a significant improvement in median survival (14 months versus 9 months) and 5-year survival (26% versus 0%; p < 0.0001). The incidence of local failure (defined as persistent disease or recurrence) at 1 year was significantly decreased in the combined modality arm (45% versus 68%; p = 0.0123). Although randomization was discontinued early because of the positive results, an additional 69 patients treated with the same CRT regimen had similar results (3-year survival 30%). Despite a survival benefit, there was an unacceptably high local failure rate (45%) in RTOG 85-01, suggesting that definitive CRT should be reserved for patients who are medically precluded from surgery.
Chemotherapy for metastatic esophageal cancer
Median survival for good performance status patients treated with combination chemotherapy for advanced unresectable or metastatic esophageal cancer ranges from 8 to 11 months in randomized studies (Table 3) . [35] [36] [37] The majority of studies have included both histologic subtypes along with a mixed group of esophageal, GEJ, and gastric tumor patients. With the relatively increasing incidence of EAC, randomized studies have frequently included esophageal, GEJ, and gastric adenocarcinoma patients, and retrospective analysis of these studies does not seem to show a difference in response to chemotherapy or survival, on the basis of tumor location. 38 Response rates from platinum/fluoropyrimidine combination studies have ranged from 24% to 58% with median survival of 8 to 16 months. 36, 39 ECF was compared with a previous reference regimen, fluorouracil, doxorubicin, and methotrexate (FAMTX) in 274 patients with advanced GEJ cancer. [40] [41] [42] This study included approximately 10% of patients who had surgical resection of their tumors after initial chemotherapy, indicating a more favorable cohort than subsequent phase III studies. Median survival was 8.7 months with ECF and 6.1 months with FAMTX, p value was 0.0005, response rates were 46% for ECF and 21% for FAMTX, respectively. Subsequently, ECF was compared with combination cisplatin, fluorouracil, and mitomycin (MCF). This study demonstrated similar response rates and survival for each arm; however, reduced quality of life was noted with MCF, leading to ECF remaining standard of care. 43 The phase III TAX-325 study compared the three-drug combination of docetaxel, cisplatin, and fluorouracil (DCF) with the two-drug combination of cisplatin and fluorouracil in 317 advanced gastric and GEJ adenocarcinoma patients of whom approximately 20% had GEJ tumors with a primary endpoint of time to tumor progression (TTP). 44 Patients treated with DCF had a significantly prolonged TTP (5.6 months versus 3.7 months, p < 0.001) and also prolonged OS (9.2 months versus 8.6 months; p = 0.02). Quality-of-life assessments indicated that deterioration in global health status was significantly delayed in the DCF group, however, grade 3 to 4 febrile neutropenia was more than twice as common (29% versus 12%) in the DCF group, and GCSF support is now recommended with this regimen. Although DCF is a reference regimen for advanced GEJ and gastric cancer, the marginal prolongation of OS and significant toxicity with this regimen spurred the search for more effective treatments. In 2008, the REAL-2 trial compared four different three-drug combinations, ECF, epirubicin, cisplatin, and capecitabine (ECX), epirubicin, oxaliplatin, and capecitabine (EOX), and epirubicin, oxaliplatin, and infusional fluorouracil (EOF) in 1002 patients with tumors of the stomach, GEJ, or esophagus. 35 Approximately 60% of patients had esophageal or GEJ primary tumors, and 10% of the tumors had squamous histology. Efficacy was similar for all arms, both for capecitabine-containing regimens compared with fluorouracil, and oxaliplatin-based regimens compared with cisplatin. Median survival was significantly prolonged for the EOX group compared with ECF (median 11.2 versus 9.9 months), leading to EOX being proposed as a new standard first-line treatment for advanced esophageal and gastric cancer. A recent meta-analysis has also suggested advantages in PFS and OS for oxaliplatin-containing regimens over cisplatin-containing alternatives. 45 
Esophageal cancer in Asia and ethnic differences in molecular biology
Esophageal cancer is a major health problem in Asia with incidence rates in Eastern Asia between two-and fourfold than those of North America, with more than two thirds of cancers occurring in men. 1 In contrast to white populations, among Asians squamous cell carcinoma is the predominant subtype, accounting for 90% of the cases in the esophageal cancer belt, which is the region stretching from northern Iran to north-central China. 3 Several reasons for this high incidence have been proposed, including frequent consumption of very hot beverages, poor nutrition, and low intake of fruit and vegetables. 6, 46, 47 Single-gene polymorphisms in alcohol-metabolizing enzymes in certain Asian populations have also been implicated, which may predispose Asians to the development of esophageal cancer related to alcohol intake. 48, 49 Deletion or loss of heterozygosity on chromosome 3p, leading to loss of tumor-suppressor gene function has been implicated in the development of ESCC among patients in China. 50 In addition, mutations of p53 affecting codon 72 have been found in Chinese patients with ESCC at a much higher frequency than in white patients, suggesting a possible etiologic role in Asian patients. 50, 51 Reflecting the baseline incidence, randomized studies of perioperative therapy for esophageal cancer in Asia have focused on squamous tumors (Table 4) . [52] [53] [54] [55] [56] [57] [58] Earlier studies examining the role of preoperative or postoperative chemotherapy failed to demonstrate a survival advantage for systemic therapy. [52] [53] [54] Of note, Asian studies of the oral fluoropyrimidine S-1 have shown particular promise in gastric cancer, and studies are ongoing of this drug as a component of multimodality therapy for esophageal cancer and for the treatment of advanced disease.
59,60 S-1 has shown improved tolerance and comparable efficacy to 5-FU-based combination chemotherapy in a large international phase III study in gastric cancer, which included 17% of patients with metastatic GEJ tumors. 59 Although studies of perioperative therapy in Asia reported in the 1990s demonstrated similar median survival to North American and European randomized populations, more recent studies, in particular those from Japan, have shown a consistent median survival of close to 5 years, which is yet to be matched in a Western phase III trial population. 15, 32, 56 As an example median survival in two recently published phase III studies from Japan and Europe have differed dramatically despite relatively well-matched enrolled patient populations for characteristics other than histologic subtype. 10, 15 The Asian study, JCOG 9907, randomized 330 patients with stage II or III ESCC to either preoperative or postoperative chemotherapy with cisplatin/fluorouracil. 15 Median survival for the postoperative chemotherapy group was 101.3 months, and median survival for the preoperative group, though not yet evaluable, however, exceeds 5 years. 56 Although the European CROSS study, which included mainly adenocarcinoma tumors, has demonstrated the longest median survival seen to date in a large Western study at 49.4 months for the preoperative CRT group, it still lags significantly behind studies from Asia. 10 The reasons for these differences, though unclear may, however, be related to histology, extent of surgery, and perhaps more significantly, underlying genetic differences in tumor biology.
Targeted agents for esophageal cancer
Although multimodality therapy has become the standard procedure for treatment of locoregionally advanced esophageal cancer, unfortunately, more than 50% of patients will eventually develop recurrence and die from their disease. This has spurred the search for agents that target specific pathways in tumor cells vital to proliferation and metastatic spread. Although initially many of these studies involved patients with metastatic disease, these agents are now increasingly being investigated in the preoperative setting as a component of multimodality therapy. Selected current and completed studies involving molecularly targeted agents in the treatment of locoregionally advanced disease are summarized in Table 5 .
Epidermal growth factor receptor
To date, the majority of studies on perioperative targeted therapy have focused on the epidermal growth factor receptor (EGFR) pathway. The incidence of EGFR expression by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) in esophago-gastric tumors has been reported with varying expression rates of 30% to 90%, and the presence of EGFR suggests a worse prognosis. 61 ,62 EGFR overexpression varies depending on histology, with expression rates being higher in ESCC than in EAC. 63 Unlike in non-small-cell lung cancer, EGFR mutations are extremely rare in esophageal tumors, limiting the activity of the small-molecule tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, in this setting. 64 K-ras mutations are rare in esophageal cancer, and recent studies have reported that only one of 203 analyzed ESCC tumors harbored a K-ras mutation, whereas four of 117 EAC tumors were K-ras mutation positive. 65, 66 Cetuximab and panitumumab are monoclonal antibodies targeted at the epidermal growth factor (EGF) receptor and are approved for the treatment of metastatic colorectal cancer. 67, 68 Several phase II studies combining these agents with CRT are either ongoing or have completed accrual in the perioperative setting (Table 5 ). Cetuximab has undergone more extensive evaluation in esophageal cancer than any other targeted agent. In the locally advanced setting, various chemotherapeutic regimens, including cisplatin/irinotecan, carboplatin/paclitaxel, cisplatin/docetaxel, and FOLFOX have been combined with cetuximab and radiation before surgery. pCR, which is regarded as a surrogate marker of long-term survival, has ranged from 13% to 40% in these trials. With the use of cetuximab in the neoadjuvant setting it is found that the pCR rates seem to be comparable with preoperative chemoradiation alone, though perhaps with more toxicity. The Eastern Cooperative Oncology Group E2205 trial, incorporating cetuximab with chemo-radiation, closed early because of an excess of pulmonary toxicity in the treatment group. The adenocarcinoma arm of the phase III, RTOG 0436 study, comparing weekly cisplatin/paclitaxel/radiation ± cetuximab as definitive therapy in locally advanced esophageal cancer, also closed as there was no evidence of increased pCR rate in the adenocarcinoma group; however, patients with squamous cell carcinoma continue to accrue. The phase II study, ACOSOG Z4051, combining panitumumab with cisplatin, docetaxel, and radiation, recently reported a promising pCR and near pCR rate of more than 55%, and has now completed accrual. 69 It is likely that this combination will move on to phase III investigation in the near future.
In the metastatic setting, cetuximab has been combined with a multitude of regimens in the first-line setting, with many trials not mandating upfront patient selection based on EGFR positivity. A trial investigating FOLFIRI plus cetuximab with The results of the randomized phase II CALGB study 80403 combining cetuximab with one of the three randomly assigned regimens of ECF, cisplatin/irinotecan, or FOLFOX were recently reported. 71 Cetuximab plus ECF or FOLFOX had response rates of more than 40%; biomarker correlatives of EGFR expression and Kras status are currently awaited. The phase III EXPAND study did not demonstrate any benefit to the addition of cetuximab to cisplatin/capecitabine in recently reported data.
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The REAL-3 trial in the United Kingdom is attempting to build on the REAL 2 study by randomizing patients with advanced GEJ tumors to EOX ± panitumumab. The doses planned originally resulted in significant toxicities, with an 80% rate of grade 3 diarrhea. The study was halted for a period of time but was subsequently resumed with lower doses of capecitabine and oxaliplatin and standard dosing of panitumumab at 6 mg/kg every 2 weeks. 73 To date, it is not clear whether the addition of monoclonal antibodies to chemotherapy is warranted because of the conflicting data from the many small trials that have been performed. In the secondline setting and beyond, preliminary data involving EGFRdirected therapy has been disappointing.
The TKIs, erlotinib and gefitinib, have limited activity in locally advanced disease in the first-or second-line metastatic setting. Gefitinib, in addition to perioperative 5FU/cisplatin/ radiation, was evaluated in 80 patients with locally advanced disease and demonstrated a trend toward an improved 3-year OS in the gefitinib arm (40% versus 28%; p = 0.06). 74 Maintenance gefitinib was poorly tolerated postoperatively. In the second-line metastatic setting, results for both TKIs have also been disappointing. Response rates have ranged from 3% to 11% with OS of 4.5 months to 5.1 months. 64, 75 The SWOG 0127 phase II trial evaluated first-line erlotinib in advanced disease, patients were stratified into GEJ (44 patients) and gastric (26 patients). 76 There were no responses in patients with gastric cancer, and an ORR of 9% was seen in GEJ patients. No EGFR or EGFR gene amplifications were detected in 54 samples, indicating that the tumor biology of upper gastrointestinal tumors is not conducive to EGFR-directed smallmolecule TKI therapy.
HER-2/neu therapy
The human epidermal growth factor receptor 2 (HER2) pathway is up-regulated in 12% to 14% of EAC tumors and less than 1% of squamous tumors. 77, 78 The phase III ToGA study compared a cisplatin/fluoropyrimidine combination plus or minus trastuzumab as first-line therapy for metastatic gastric or GEJ adenocarcinoma overexpressing HER2. 79 In this pivotal trial, 22.1% of tumors were found to be Her-2/neu positive by IHC or FISH, and 594 patients were randomly assigned to study treatment (trastuzumab 54 ESCC, esophageal squamous cell carcinoma; OS, overall survival; (ns), difference not statistically significant; (s), difference statistically significant; C, chemotherapy; Sx, surgery; cGy, centiGray; CRT, concurrent chemo-radiation; FU, fluourouracil.
plus chemotherapy, n = 298; chemotherapy alone, n = 296), of whom 584 were included in the primary analysis (n = 294; n = 290). The report of this study outlines in detail the mechanism used to assess HER2 positivity. 79 Median OS was 13.8 months (95% CI, 12-16) in those assigned to trastuzumab plus chemotherapy, compared with 11.1 months (10-13) in those assigned to chemotherapy alone (HR 0.74; 95% CI, 0.60-0.91; p = 0.0046). The ToGA trial is the first positive phase III trial of a targeted agent in upper GI tumors. Unfortunately, because of the limited incidence of HER-2 positive disease this strategy will be beneficial only for a minority of patients. EGFR, epidermal growth factor receptor; HER-2, human epidermal growth factor receptor 2; pCR, pathological complete response; GEJ, gastro-esophageal junction; ESCC, esophageal squamous cell carcinoma; EAC, esophageal adenocarcinoma; VEGF, vascular endothelial growth factor receptor; FGFR, fibroblast growth factor receptor; FISH, fluorescence in situ hybridization; PFS, progression-free survival; OS, overall survival; CHFR, checkpoint with Forkhead-associated and RING finger domains. PARP, poly-ADP-ribose polymerase.
The targeting of HER2 is now being assessed for earlierstage disease in the ongoing phase III RTOG 1010 neoadjuvant study, combining trastuzumab with paclitaxel, carboplatin, and radiation for HER2-positive patients (Table 5) . 80 Lapatinib, which is a dual small-molecule TKI of both EGFR and HER2, has been evaluated in two phase II trials in unselected advanced esophageal and GE junction adenocarcinomas, and seems to have limited activity with response rates varying from 0% to 9%. 81, 82 The ongoing phase III LOGIC trial, evaluating capecitabine/oxaliplatin ± lapatinib as firstline therapy, and the TYTAN trial, a phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy, will help define its role in preselected patients with HER2 FISH-amplified tumors.
Vascular endothelial growth factor
In esophageal cancer, vascular endothelial growth factor (VEGF) is overexpressed in 30% to 60% of patients, and several studies have demonstrated a correlation between high levels of VEGF expression and advanced stage and poor survival postesophagectomy. [83] [84] [85] [86] Anti-VEGF strategies that have been evaluated in esophageal cancer include the use of the monoclonal antibody, bevacizumab, and the multitarget TKIs, sorafenib and sunitinib. In operable esophageal cancer, a phase II study investigated the addition of bevacizumab to cisplatin/irinotecan as induction therapy with concurrent radiation before esophagectomy. 87 Squamous cell histology was excluded because of bleeding concerns. Although the addition of bevacizumab was well tolerated, it did not demonstrate improved efficacy, with pCR rates inferior to that of historical controls. The ongoing MAGIC II trial is a multicenter, open-label, phase II/III randomized trial in the United Kingdom, which is currently evaluating perioperative ECX ± bevacizumab. The target accrual of 950 patients is expected by 2013.
In the metastatic setting, a multicenter, phase II, firstline trial evaluated the addition of bevacizumab to cisplatin/ irinotecan in 47 patients. 88 The addition of bevacizumab significantly improved time to tumor progression (TTP) (8.3 months; 95% CI, 5.5-9.9 months), compared with historical TTP of 5 months, and OS was 12.3 months (95% CI, 11.3-17.2 months). A second trial combined bevacizumab with modified DCF in 44 patients. The overall response rate was 67%, median PFS was 12 months (95% CI, 8.8-26 months), and median OS 16.8 months. 89 Toxicities were similar to the known side effects of bevacizumab use, although gastric perforation was reported in approximately 2% of cases. In the second-line setting, the combination of bevacizumab and docetaxel has been evaluated in 26 patients and demonstrated an impressive overall response rate of 24% in 17 evaluable patients, although with a 12% risk of a GI bleed and 8% risk of a thromboembolic event. 90 The recently published AVAGAST study showed that, although the addition of bevacizumab to chemotherapy prolonged PFS, there was no evidence of an OS advantage. 91 Attempts to develop predictive biomarkers are ongoing. 92 Sorafenib and sunitinib have been evaluated in a number of phase II clinical trials in metastatic upper GI tumors that demonstrated limited activity. 93, 94 Strategies targeting VEGF have ultimately been disappointing to date, and at present patients are advised not to receive these agents outside an approved clinical trial.
MET
The c-MET oncogene is reported to be amplified in approximately 10% to 15% of upper GI tumors; however, this incidence may be as low as 2% in Western populations. 95 Expression has been correlated with adenocarcinoma histology, more advanced stage, and worse prognosis. 96, 97 Several agents targeting MET are in clinical development for the treatment of gastro-esophageal cancer. Onartuzumab (MetMAb) is a humanized monovalent monoclonal antibody-targeting MET, which is being investigated in a randomized phase II study in combination with mFOLFOX6 for metastatic HER2-negative GEJ adenocarcinoma. 98 Recently crizotinib has shown preliminary efficacy in a small population of patients with advanced GEJ adenocarcinomas harboring c-MET amplification. 95 The monoclonal antibody, rilotumumab (AMG-102), which targets MET, is currently undergoing phase III investigation combined with ECX chemotherapy in advanced MET IHC-positive gastric or GEJ cancer. 99 Rilotumumab combined with FOLFOX versus FOLFOX/panitumumab is also being studied in unselected advanced GEJ tumor patients in a firstline randomized phase II study in France.
100 Tivantinib (ARQ-197), a selective MET TKI, is being combined with FOLFOX in the first-line setting for metastatic GEJ and gastric cancer patients not selected for MET expression. Ongoing studies of MET-targeted agents are summarized in Table 5 .
Future Directions
The ongoing Eastern Cooperative Oncology Group 2208 trial is investigating the role of IMC-A12 (cixutumumab), a monoclonal antibody targeting insulin-like growth factor-1R, as a second-line agent in metastatic esophageal cancer given with weekly paclitaxel. iMAB362, a monoclonal antibody-targeting cell-surface antigen Claudine 18.2, which is expressed in 70% of gastric cancers and 30% of esophageal cancers, is in early-phase development. Small-molecule fibroblast growth factor receptor (FGFR) kinase inhibitors are also in clinical development for fibroblast growth factor receptor 2-amplified advanced EAC, GEJ cancer, and gastric cancer. An additional area of research involves epigenetic therapy, and we are currently evaluating checkpoint with Forkheadassociated and RING finger domains (CHFR) gene methylation as a predictor of sensitivity to taxane-based chemotherapy in both operable and metastatic esophageal cancer (Table 5) . Epigenetic therapeutic trials using the demethylating agent, 5-azacytidine, given in combination with a histone deacetylase inhibitor are also in development.
The hedgehog pathway is another potential target with the oral TKI, vismodegib, which has recently been approved for the treatment of basal cell carcinoma and is being investigated in combination with chemotherapy for advanced GEJ tumors ( Table 5) .
Next-generation sequencing of esophageal cancer is an exciting area of investigation with recent evidence reporting the pivotal role of NOTCH1-mediated signaling in ESCC tumor suppression.
101 NOTCH1 is frequently mutated in ESCC, and plays a key role in tumorigenesis, although nonmutually exclusive mutations of TP53 also occur. Recently, the exomic sequencing of ESCC and EAC in the United States and China has suggested that NOTCH1 mutations occur in ESCC in America, but not in China, and that these mutations may lead to loss of tumor-suppressor function. FBXW7 mutations may also drive ESCC tumorigenesis independent of NOTCH1 through loss of tumor suppression function. In EAC, carcinogenic mutations seem to be present from the development of Barrett's esophagus, suggesting that important events occur very early in tumorigenesis.
CONCLUSION
In the last few years, randomized controlled trials have shown a significant survival advantage for preoperative CRT with a predicted 5-year survival of up to 49% for the multimodality approach, demonstrated in the CROSS trial. Unfortunately, significant breakthroughs in the use of targeted agents has been limited to the addition of trastuzumab to chemotherapy for HER2-positive advanced GEJ tumors. Ethnic differences are becoming apparent but next-generation sequencing has failed to demonstrate significant oncogenic targets, indicating that alternative approaches, such as epigenetic and immunotherapeutic strategies, should be investigated if we are to improve outcomes in this heterogenous and difficult-to-treat tumor.
